Methodological Concerns in PARP Inhibitor Trials Leave Unanswered Questions for mCRPC

Daniel A. González-Padilla, of the Clínica Universidad de Navarra in Spain, shares his thoughts on the methodological concerns of TRITON3 and PROfound for rucaparib and olaparib in treating mCRPC, including prior treatments, control arms, postprotocol treatments, and inappropriate crossover.

He also elaborates on what further overall survival data or other survival data are needed before rucaparib or olaparib should be considered standard of care in daily practice for these patients.

Hear what Drs. Catherine Marshall, Melissa Reimers, and Tanya Dorff had to say about PARP inhibitor utility in this patient population in a previous roundtable discussion.